Except for patient 4 in the without EMD group (Ptwithout 4), who achieved SD following anti‐BCMA CAR‐T cell therapy, the MM cell percentages in the bone marrow and M protein levels in peripheral blood decreased to different degrees in all patients with R/R MM anti‐BCMA CAR‐T cell infusion. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.